FDA Required Outcomes Data For Cleviprex Priority Review, Proposed Label
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s determination that The Medicines Company’s Cleviprex did not actually show a significant benefit over other intravenous antihypertensives caused the agency to make a rare move, and downgrade the application from a priority to a standard review.
You may also be interested in...
Behind The Approval Letter: A Year Of Drug Review Profiles
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
Sponsors who plan to seek priority review status need to show a superior effect on clinical outcomes, an examination of priority review requests rejected by FDA suggests